Crinetics Pharmaceuticals Inc (CRNX)

Jan 10, 2025, 5:15 PM EST - 7 days ago

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 10, 2025, 7:00 AM EST - 7 days ago

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Jan 6, 2025, 8:00 AM EST - 11 days ago

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 5:53 AM EST - 15 days ago

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Dec 10, 2024, 8:44 PM EST - 5 weeks ago

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 9, 2024, 8:00 AM EST - 5 weeks ago

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Nov 14, 2024, 4:05 PM EST - 2 months ago

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Nov 12, 2024, 11:00 PM EST - 2 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:07 PM EST - 2 months ago

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Nov 12, 2024, 4:05 PM EST - 2 months ago

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 4:05 PM EST - 2 months ago

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 10, 2024, 4:40 PM EDT - 3 months ago

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 8, 2024, 11:55 PM EDT - 3 months ago

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Oct 8, 2024, 4:01 PM EDT - 3 months ago

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 26, 2024, 4:05 PM EDT - 4 months ago

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Sep 10, 2024, 4:40 PM EDT - 4 months ago

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 29, 2024, 4:05 PM EDT - 5 months ago

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT - 5 months ago

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 8, 2024, 9:23 PM EDT - 5 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:30 AM EDT - 5 months ago

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

Jul 18, 2024, 4:05 PM EDT - 6 months ago

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 10, 2024, 7:29 PM EDT - 6 months ago

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 18, 2024, 4:30 PM EDT - 7 months ago

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

Jun 10, 2024, 6:35 PM EDT - 7 months ago

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2024, 12:00 PM EDT - 8 months ago

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Jun 3, 2024, 12:00 PM EDT - 8 months ago

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)

May 30, 2024, 4:05 PM EDT - 8 months ago

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.

May 23, 2024, 5:45 AM EDT - 8 months ago

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 22, 2024, 8:00 AM EDT - 8 months ago

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

May 11, 2024, 10:09 AM EDT - 8 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Call Transcript

May 10, 2024, 5:38 PM EDT - 9 months ago

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2024, 4:05 PM EDT - 9 months ago

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 4:05 PM EDT - 9 months ago

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 11, 2024, 4:05 PM EDT - 10 months ago

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 3, 2024, 1:47 PM EDT - 10 months ago

Under-the-radar biotech bets

MRUS SNDX XBI

Mar 19, 2024, 6:09 AM EDT - 10 months ago

Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study

Mar 19, 2024, 6:00 AM EDT - 10 months ago

Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

Mar 12, 2024, 4:05 PM EDT - 11 months ago

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Mar 11, 2024, 4:05 PM EDT - 11 months ago

Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 29, 2024, 2:20 PM EST - 11 months ago

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29, 2024, 5:46 AM EST - 11 months ago

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:05 PM EST - 11 months ago

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 28, 2024, 8:00 AM EST - 11 months ago

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

Feb 14, 2024, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Feb 12, 2024, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 10, 2024, 4:33 PM EST - 1 year ago

Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 18, 2023, 4:05 PM EST - 1 year ago

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Dec 11, 2023, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 28, 2023, 3:36 PM EST - 1 year ago

Crinetics Pharmaceuticals: Some Caution Warranted

Nov 20, 2023, 4:05 PM EST - 1 year ago

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences